Effects of Rivaroxaban on Renal Function in Non-valvular atrial Fibrillation Patients with Chronic Kidney Diseases
- Conditions
- on-valvular atrial Fibrillation Patients with Chronic Kidney Diseases
- Registration Number
- JPRN-UMIN000016296
- Lead Sponsor
- Saga University Faculty of Medicine, Department of Cardiovascular Medicine
- Brief Summary
There was no significant intergroup difference in the magnitude of changes in UACR (p=0.52).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 58
Not provided
Patients meeting any of the following criteria were not eligible for inclusion in this study. (1)Patients with onset of acute coronary syndrome or stroke within 6 months. (2)Patients scheduled to undergo percutaneous coronary intervention (PCI) or catheter ablation. (3)Patients receiving dual ntiplatelet therapy (DAPT). (4)Patients with a history of hypersensitivity to the components of warfarin or rivaroxaban. (5)Patients with active bleeding (non-major clinically relevant bleeding events, such as intracranial hemorrhage, gastrointestinal hemorrhage). (6)Patients with hepatic disorders associated with coagulation abnormalities. (7)Patients with moderate or severe hepatic disorder (equivalent to Child-Pugh classification B or C). (8)Patients with renal failure (creatinine clearance < 30 mL/min). (9)Pregnant women or women with pregnancy potential. (10)Patients receiving HIV protease inhibitors (ritonavir, atazanavir, indinavir, etc.). (11)Patients receiving oral or intravenous administration of azole antifungal drugs (itraconazole, voriconazole, or ketoconazole). (12)Patients receiving vitamin K agents for osteoporosis. (13)Patients receiving iguratimod. (14)Patients with acute bacterial endocarditis. (15)Patients who did not give informed consent. (16)Other patients considered by the investigator to be unsuitable for participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint was the change amount in urinary albumin 3 months after registration.
- Secondary Outcome Measures
Name Time Method The secondary endpoints were changes amount in endothelial functions, inflammatory markers, renal function markers, osteocalcin markers.